ZACKS

搜索文档
3 Financial Stocks Benefiting From Fed Policy Shifts in 2025
ZACKS· 2025-08-12 22:05
Key Takeaways Financial stocks have risen 9.1% YTD, outpacing the broader market in 2025.Fed rate cut expectations and strong economic data boost sector outlook.AB, IBKR and JHG flaunt improved earnings estimates and strong VGM Scores.Financial stocks have recorded noteworthy gains in 2025. The S&P 500 Financial Select Sector SPDR ETF has outpaced the broader market, rising 9.1% as of July. This has been supported by solid economic indicators, regulatory tailwinds and renewed confidence in capital markets. ...
Should You Buy Aris Mining Stock After a 70% Surge in 6 Months?
ZACKS· 2025-08-12 22:05
Key Takeaways Aris Mining shares have soared 70.1% in six months, outpacing the industry and the S&P 500.Segovia expansion boosts capacity by 50%, targeting 300,000 ounces output in 2026.ARMN trades at 4X forward P/E, a steep discount to the gold mining industry average.Aris Mining Corporation's (ARMN) shares have popped 70.1% over the past six months, outperforming the Zacks Mining – Gold industry’s rise of 35.9% and the S&P 500’s increase of 4.4%. The rally has been driven by a spike in gold prices and AR ...
Is SoundHound AI a Lucrative Bet on Long-Term Potential on Voice AI?
ZACKS· 2025-08-12 22:01
Key Takeaways SOUN Q2 revenue jumped 217% to $42.7M, beating estimates, with EPS loss narrowing to $0.03.Management raised 2025 sales outlook in the range of $160 to 178M, nearly doubling revenues year over year.Vision AI, Polaris integration, and major automotive wins bolster SoundHounds voice AI momentum.SoundHound AI Inc. (SOUN) — the conversational and agentic artificial intelligence (AI) specialist — reported impressive second-quarter 2025 earnings results. SOUN reported quarterly adjusted loss of $0.0 ...
Is Trending Stock Duolingo, Inc. (DUOL) a Buy Now?
ZACKS· 2025-08-12 22:01
股票表现 - 过去一个月公司股价回报率为-9.5% 同期Zacks S&P 500指数上涨2% 所属科技服务行业上涨11.6% [1] 盈利预测修正 - 当前季度每股收益预期为0.72美元 同比增长46.9% 过去30天共识预期上调4% [4] - 本财年共识盈利预期3.12美元 同比增长66% 过去30天上调7.7% [4] - 下一财年盈利预期4.43美元 同比增长42% 过去一个月上调5% [5] - 盈利预测修正与短期股价走势存在强相关性 [3] 收入增长预测 - 当前季度收入预期2.6056亿美元 同比增长35.3% [10] - 本财年收入预期10.2亿美元 同比增长36.3% [10] - 下一财年收入预期12.8亿美元 同比增长25.8% [10] 最新财报表现 - 上季度收入2.5226亿美元 同比增长41.5% 超出共识预期4.87% [11] - 上季度每股收益0.91美元 同比增78.4% 超出预期65.45% [11] - 过去四个季度三次超出盈利预期 每次均超收入预期 [12] 估值分析 - 当前估值高于同业水平 价值风格评分F级 [16] - 需关注市盈率(P/E) 市销率(P/S) 市现率(P/CF)等指标与历史及同业对比 [14] 综合评级 - Zacks评级为3级(持有) 预示短期表现可能与大盘同步 [6][17]
Is the Options Market Predicting a Spike in Renasant Stock?
ZACKS· 2025-08-12 21:56
Investors in Renasant Corporation (RNST) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 19, 2025 $35.00 Put had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could a ...
JPM or MS: Which Investment Banking Powerhouse is the Better Buy Now?
ZACKS· 2025-08-12 21:56
投资银行行业概况 - 摩根大通(JPM)和摩根士丹利(MS)是华尔街投行业务的领军企业 涉及数十亿美元的并购咨询 高调IPO承销以及动荡资本市场的运作 [1] - 行业长期前景稳健 但短期动能受特朗普关税政策影响 2025年上半年投行费用已恢复增长趋势 [2] - 市场波动性增加反而推动交易业务收入增长 经济不确定性对投行业务并非全然负面 [5][10] 摩根大通(JPM)业务表现 - 2024年投行费用飙升36%至89 1亿美元 2025年上半年同比再增10%至46 8亿美元 全球市场份额达8 9% [2][3][9] - 交易业务受益于关税不确定性 2024年及2025年上半年市场收入显著增长 [5] - 净利息收入(NII)占总收入近半 2025年预计增长3%至955亿美元 利息收益资产净收益率趋于稳定 [6] - 当前市盈率14 52倍 低于同业 净资产收益率(ROE)16 93% 年内股价涨幅20 8% [15][16][12] 摩根士丹利(MS)业务表现 - 2024年投行收入增长36%至67 1亿美元 但2025年仅同比微增1% [7][8] - 财富与资产管理业务收入占比从2010年26%跃升至2024年55% 2025年上半年客户资产达8 2万亿美元 [11] - 交易业务表现优异 受关税不确定性和宏观经济逆风推动 [8][10] - 当前市盈率15 56倍 ROE15 20% 年内股价涨幅14 4% [15][16][12] 财务预期比较 - 摩根大通2025年营收预计微降 2026年增长3 4% 盈利预期近期上调 [18][20] - 摩根士丹利2025/2026年营收预计增长8 3%/4 2% 盈利预期增幅达10 9%/8% 分析师更为看好 [20][22] 综合对比 - 摩根大通在投行市场份额 交易业务弹性及多元化收入结构方面占优 估值更具吸引力 [9][15][23] - 摩根士丹利通过财富管理转型降低业务波动性 长期资产积累接近10万亿美元目标 [11] - 当前摩根大通获Zacks1评级(强力买入) 摩根士丹利为3评级(持有) [23]
Fast-paced Momentum Stock Beauty Health (SKIN) Is Still Trading at a Bargain
ZACKS· 2025-08-12 21:51
Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves a ...
Adecco (AHEXY) Is Attractively Priced Despite Fast-paced Momentum
ZACKS· 2025-08-12 21:51
Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth po ...
Enerflex (EFXT) Is Attractively Priced Despite Fast-paced Momentum
ZACKS· 2025-08-12 21:50
Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves a ...
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up
ZACKS· 2025-08-12 21:30
Key Takeaways Exact Sciences posted Q2 EPS of $0.22 versus a loss of $0.09 last year, beating estimates.EXAS' Q2 revenues rose 16% to $811.1M, led by Cologuard and Oncotype growth.EXAS lifts 2025 revenue forecast to $3.13-$3.17B, with the EBITDA outlook also increased.Exact Sciences Corporation (EXAS) reported earnings per share (EPS) of 22 cents in the second quarter of 2025 compared to the Zacks Consensus Estimate of a loss of 2 cents. The reported figure compares favorably with a loss of 9 cents in the s ...